Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy
Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
whether Nilotinib at the two sequential dosage forms will induce quicker and deeper response
in those patients, and if FISH on PB (Peripheral blood) would be an effective way to monitor
response compared to conventional cytogenetics on bone marrow (BM) sample
Phase:
Phase 4
Details
Lead Sponsor:
King Abdullah International Medical Research Center